ZVRA Stock — Zevra Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We are focused on expanding patient access, progressing our pipeline toward key milestones, and delivering meaningful therapeutics.

Source: 10-K FY2025 via SEC EDGAR

Share price

$12.01

Market cap

$714.7M

Cash

$270.9M

Enterprise value

$443.8M

Balance sheet

Cash	$270.9M
Debt	$0.0M
Net cash	$270.9M
Enterprise value	$443.8M
Basic shares	59.5M shares
Fully diluted shares	69.3M shares
Fully diluted market cap	$832.2M
Cash per share	$4.55
Quarterly burn	+$17.0M generated

Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.

Share structure

Common

59.5M

Pre-funded warrants

0.0M

Options

5.5M

RSUs

1.8M

Warrants

2.5M

Converts

—

Conv preferred

0.0M

ESPP reserve

—

FDSO

69.3M

Cap table as of 2025-12-31.

Price history

Loading ZVRA daily closes…

Loading price history…

Next catalyst

Sodium phenylbutyrate · Feb 12 - Mar 26 in 13 wks · Phase 2 · Medium-chain Acyl-CoA Dehydrogenase Deficiency

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 12 - Mar 26 in 13 wks	Sodium phenylbutyrate	Phase 2	Medium-chain Acyl-CoA Dehydrogenase Deficiency	—
Aug 12 - Sep 23 in 9 mo	Sodium phenylbutyrate	Phase 1	Combined D,L-2-hydroxyglutaric Aciduria	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

celiprolol

Phase 3 · Active Modality: small molecule

Target adrenoceptor

Partnerships Acquired via Acer Therapeutics (November 2023)

Indications

Vascular Ehlers-Danlos syndrome (VEDS) (Phase 3)

Status note Phase 3 DiSCOVER trial (event-driven, 150 patients planned, celiprolol vs placebo) ongoing; recruitment restarted mid-2024 with 66 enrolled as of June 30, 2026. Orphan Drug Designation (2015); prior NDA received CRL requesting an adequate and well-controlled trial.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06773026	Phase 2	Recruiting	Collaborator	Jerry Vockley, MD, PhD	—	Medium-chain Acyl-CoA Dehydrogenase Deficiency	—
NCT07125066	Phase 1	Enrolling by invitation	Collaborator	Jerry Vockley, MD, PhD	—	Combined D,L-2-hydroxyglutaric Aciduria	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Jerry Vockley, MD, PhD on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Stonepine Capital	258,701	-221,299	2.82%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ZVRA — Zevra Therapeutics Inc. ☆